Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients With Pathologically Confirmed Cancer Refractory to Conventional Therapy

NCT03941262 is registered in ClinicalTrials.gov with NKGen Biotech, Inc. as lead sponsor.

NCT NCT03941262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03941262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients With Pathologically Confirmed Cancer Refractory to Conventional Therapy
Lead sponsor
NKGen Biotech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 15, 2019
Completion date
February 17, 2023
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, metastatic cancer, recurrent cancer, refractory cancer, solid tumor, adult, unresectable carcinoma